Leflunomid Al (Leflunomide)

Leflunomide blocks dihydroorotate dehydrogenase, an enzyme required for de novo pyrimidine synthesis. This limits the production of nucleotides needed for activated lymphocyte proliferation, thereby dampening the immune response that drives inflammatory joint disease.

The dosage of Leflunomid Al is determined by the prescribing clinician based on the patient’s condition, disease severity, and laboratory monitoring. Physicians typically start with a loading dose followed by a maintenance dose, but the exact regimen must be individualized and documented in the prescription.

Leflunomid Al is classified as pregnancy category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. Women of child‑bearing potential must use effective contraception, and the drug should not be used while breastfeeding.

To request Leflunomid Al, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative DMARD is methotrexate. Both suppress immune activity, but leflunomide primarily inhibits pyrimidine synthesis, whereas methotrexate interferes with folate metabolism. Leflunomide may be preferred when patients cannot tolerate methotrexate‑related liver toxicity, but each drug has distinct safety profiles that guide selection.

Leflunomid Al tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Leflunomid Al is taken orally as a whole tablet with a glass of water. It is usually swallowed whole and not crushed or chewed. The tablet should be taken with or without food as directed by the prescriber.

The most serious adverse events include hepatotoxicity (significant liver enzyme elevation or liver injury), severe infections due to immunosuppression, and bone‑marrow suppression leading to low blood counts. Patients should undergo regular laboratory monitoring and report any signs of liver dysfunction, infection, or unusual bruising.

Leflunomid Al should not be used by pregnant women, individuals with severe liver disease, patients with known hypersensitivity to leflunomide, or those receiving live vaccines. Caution is also advised for patients with significant renal impairment or uncontrolled hypertension.